Biodexa Pharmaceuticals plc (BDRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 67/100 (HIGH), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients
- Interim results for the six months ended June 30, 2026
- Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
- Result of Annual General Meeting
- Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
- Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
- European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
- BDRX: Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Far
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biodexa Pharmaceuticals plc.
Full BDRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.